Chemotherapy combination with erythropoiesis-stimulating agent

This page covers all Chemotherapy combination with erythropoiesis-stimulating agent drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting DNA (epirubicin, cyclophosphamide), microtubules (paclitaxel), erythropoietin receptor (dabepoetin alfa).

Targets

DNA (epirubicin, cyclophosphamide), microtubules (paclitaxel), erythropoietin receptor (dabepoetin alfa)

Phase 3 pipeline (1)

• Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa · GBG Forschungs GmbH · Oncology
  This combination regimen uses chemotherapy agents (epirubicin, cyclophosphamide, paclitaxel) to damage cancer cell DNA and inhibit microtubule function, while dabepoetin alfa stimulates red blood cell production to counteract chemotherapy-induced anemia.

Patent intelligence

• chemotherapy combination with erythropoiesis stimulating agent patent landscape — aggregated cliff calendar, attackable patents, originator estates